Dr. Aboulafia on Targeted Therapy in Tenosynovial Giant Cell Tumor

Video

Albert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.

Albert J. Aboulafia, MD, medical director of the Weinberg Cancer Institute at MedStar Franklin Square Medical Center, discusses targeted therapy options in tenosynovial giant cell tumor (TGCT).

Currently in the TGCT space, there are few precision medicine initiatives, says Aboulafia. A phase I trial is examining the use of targeted therapies within TGCT, and could provide some insight into this heterogenous disease.

Soft tissue sarcomas, including synovial sarcoma, myxoid liposarcoma, and alveolar rhabdomyosarcoma, have translocations or molecular rearrangements, says Aboulafia. A small number of patients have targetable mutations. The National Cancer Institute-MATCH trial shows that if an NTRK fusion, for example, is detected with molecular profiling, the patient can be treated with NTRK-targeted therapy.

Rather than the sarcoma or tumor type, it is the mutation that is specifically targeted, Aboulafia concludes.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.